The Health Ministry has introduced new regulations aimed at suspending manufacturing licenses for medicines that do not meet quality criteria. This swift action is intended to stop subpar drugs from reaching patients and to minimize their circulation during the regulatory review. Licenses can be suspended based on government analysts’ findings that indicate deficiencies.